One key component of any successful business venture is its ability to differentiate itself from the competition.
BET Pharm, LLC has licensed the BioRelease, state of the art, delivery platforms. BioRelease refers to a group of proprietary vehicles that enables the veterinary practitioner to deliver various drugs in a precise release pattern following intramuscular injection. These vehicles include shorter acting liquid formulations designed for controlled release from 12 hours to 12 days and longer acting Lactide-glycolide MICROPARTICLE formulations (as used in bioabsorbable sutures) designed to release from 20 days to 100 days (i.e. 30 day Altrenogest; 100 day Ivermectin formulations). These vehicles are biocompatible and work for a variety of drug classes including steroids, NSAIDs, peptides, thyroxine, anthelmentics, D2-receptor agonists and antibiotics.
What this means in terms of animal health, is the probability of compliance is significantly increased especially when the requirement for daily administration of a drug is present. Compliance is even more likely since the veterinarian is the person giving the injections of the compound, as most actives only have to be injected once per week or once per month.